AAV Capsid Mutations Enhance Tissue Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors exhibit poor gene transfer efficiency in major target tissues, limiting their effectiveness for gene therapy and research applications.
Innovation Solution
Development of novel AAV variants with distinct tissue targeting capabilities, including AAV3B variants that specifically target human hepatocytes and heart tissue, achieved through amino acid variations in capsid proteins and the use of recombinant AAVs with specific transgenes for gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV vectors are used for gene delivery, then safety profile is maintained, but gene transfer efficiency in major target tissues is poor
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the AAV capsid protein through site-directed mutagenesis. Specific amino acid substitutions (e.g., K296E, K296Q, K296R, K296M) were introduced to alter the capsid's tissue tropism properties, enabling enhanced transduction of cardiac and skeletal muscle tissues while maintaining the safety profile of AAV vectors
Solution Approach 2:
The patent applies local quality by creating capsid variants with specific localized amino acid modifications at position 296. This targeted modification approach allows the capsid to maintain its overall structure and safety properties while acquiring enhanced local affinity for muscle tissue receptors, thereby improving gene transfer efficiency specifically in cardiac and skeletal muscle without affecting other tissues
2Adaptability or versatility
If AAV vectors are engineered for specific tissue targeting, then tissue tropism is enhanced, but vector complexity increases
Solution Approach 1:
The patent applies local quality by introducing a single point mutation at amino acid position 296 of the capsid protein. This localized modification strategy enables specific tissue targeting capability while minimizing the increase in vector complexity, as only one amino acid position was altered rather than extensive engineering of the entire capsid structure
Solution Approach 2:
The patent applies parameter changes by systematically testing different amino acid substitutions at position 296 (E, Q, R, M) to optimize tissue targeting. This approach allows for precise tuning of the capsid's interaction with tissue receptors, achieving enhanced adaptability through simple parameter modification rather than complex structural redesign
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.